Cargando…

Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study

INTRODUCTION: This study aimed to analyze the diversity of intestinal flora in patients with chronic hepatitis B (CHB) and investigate the effect of entecavir on the intestinal flora in these patients. METHODS: Thirty patients with CHB and 30 healthy controls were recruited from the Department of In...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yu-Xia, He, Cheng-Zhi, Wang, Ying-Xin, Ai, Zi-Sheng, Liang, Ping, Yang, Chang-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954982/
https://www.ncbi.nlm.nih.gov/pubmed/33111216
http://dx.doi.org/10.1007/s40121-020-00355-w
_version_ 1783664171556012032
author Lu, Yu-Xia
He, Cheng-Zhi
Wang, Ying-Xin
Ai, Zi-Sheng
Liang, Ping
Yang, Chang-Qing
author_facet Lu, Yu-Xia
He, Cheng-Zhi
Wang, Ying-Xin
Ai, Zi-Sheng
Liang, Ping
Yang, Chang-Qing
author_sort Lu, Yu-Xia
collection PubMed
description INTRODUCTION: This study aimed to analyze the diversity of intestinal flora in patients with chronic hepatitis B (CHB) and investigate the effect of entecavir on the intestinal flora in these patients. METHODS: Thirty patients with CHB and 30 healthy controls were recruited from the Department of Infectious Diseases and Department of Gastroenterology of Shanghai Tongji Hospital between January 2017 and December 2018. Stool samples were collected for the detection of intestinal flora by high-throughput sequencing. Patients with CHB received antivirus therapy with entecavir for 8 weeks. The biochemical and virological responses were assessed and the intestinal flora were compared. RESULTS: After entecavir treatment, the blood levels of alanine aminotransferase (ALT), interleukin-6 (IL-6), IL-8, tumor necrosis factor (TNF), and hepatitis B virus (HBV) DNA reduced significantly in patients with CHB and the species abundance of intestinal flora increased markedly. In patients with CHB, the unique genera included Butyrivibrio, Phaseolus acutifolius, and Prevotellaceae NK3B31 group before treatment and Howardella, Candidatus Stoquefichus, Citrobacter, Dysgonomonas, Faecalicoccus, Methanobrevibacter, Mitsuokella, Mobilitalea, Succinivibrio, Gluconobacter, and Plesiomonas after treatment. The abundance of the following genera increased significantly after entecavir treatment in patients with CHB: Clostridium sensu stricto 1, Erysipelotrichaceae UCG-007, and Intestinibacter. The abundance of Streptococcus, Atopobium, and Murdochiella reduced markedly after entecavir treatment in patients with CHB. CONCLUSION: After 8-week entecavir treatment, the blood biochemical, immunological, and virological responses improved significantly, the species abundance of intestinal flora increased markedly, and there were unique genera in patients with CHB before and after treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40121-020-00355-w) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7954982
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-79549822021-03-28 Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study Lu, Yu-Xia He, Cheng-Zhi Wang, Ying-Xin Ai, Zi-Sheng Liang, Ping Yang, Chang-Qing Infect Dis Ther Original Research INTRODUCTION: This study aimed to analyze the diversity of intestinal flora in patients with chronic hepatitis B (CHB) and investigate the effect of entecavir on the intestinal flora in these patients. METHODS: Thirty patients with CHB and 30 healthy controls were recruited from the Department of Infectious Diseases and Department of Gastroenterology of Shanghai Tongji Hospital between January 2017 and December 2018. Stool samples were collected for the detection of intestinal flora by high-throughput sequencing. Patients with CHB received antivirus therapy with entecavir for 8 weeks. The biochemical and virological responses were assessed and the intestinal flora were compared. RESULTS: After entecavir treatment, the blood levels of alanine aminotransferase (ALT), interleukin-6 (IL-6), IL-8, tumor necrosis factor (TNF), and hepatitis B virus (HBV) DNA reduced significantly in patients with CHB and the species abundance of intestinal flora increased markedly. In patients with CHB, the unique genera included Butyrivibrio, Phaseolus acutifolius, and Prevotellaceae NK3B31 group before treatment and Howardella, Candidatus Stoquefichus, Citrobacter, Dysgonomonas, Faecalicoccus, Methanobrevibacter, Mitsuokella, Mobilitalea, Succinivibrio, Gluconobacter, and Plesiomonas after treatment. The abundance of the following genera increased significantly after entecavir treatment in patients with CHB: Clostridium sensu stricto 1, Erysipelotrichaceae UCG-007, and Intestinibacter. The abundance of Streptococcus, Atopobium, and Murdochiella reduced markedly after entecavir treatment in patients with CHB. CONCLUSION: After 8-week entecavir treatment, the blood biochemical, immunological, and virological responses improved significantly, the species abundance of intestinal flora increased markedly, and there were unique genera in patients with CHB before and after treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40121-020-00355-w) contains supplementary material, which is available to authorized users. Springer Healthcare 2020-10-28 2021-03 /pmc/articles/PMC7954982/ /pubmed/33111216 http://dx.doi.org/10.1007/s40121-020-00355-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Lu, Yu-Xia
He, Cheng-Zhi
Wang, Ying-Xin
Ai, Zi-Sheng
Liang, Ping
Yang, Chang-Qing
Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study
title Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study
title_full Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study
title_fullStr Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study
title_full_unstemmed Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study
title_short Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study
title_sort effect of entecavir on the intestinal microflora in patients with chronic hepatitis b: a controlled cross-sectional and longitudinal real-world study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954982/
https://www.ncbi.nlm.nih.gov/pubmed/33111216
http://dx.doi.org/10.1007/s40121-020-00355-w
work_keys_str_mv AT luyuxia effectofentecavirontheintestinalmicroflorainpatientswithchronichepatitisbacontrolledcrosssectionalandlongitudinalrealworldstudy
AT hechengzhi effectofentecavirontheintestinalmicroflorainpatientswithchronichepatitisbacontrolledcrosssectionalandlongitudinalrealworldstudy
AT wangyingxin effectofentecavirontheintestinalmicroflorainpatientswithchronichepatitisbacontrolledcrosssectionalandlongitudinalrealworldstudy
AT aizisheng effectofentecavirontheintestinalmicroflorainpatientswithchronichepatitisbacontrolledcrosssectionalandlongitudinalrealworldstudy
AT liangping effectofentecavirontheintestinalmicroflorainpatientswithchronichepatitisbacontrolledcrosssectionalandlongitudinalrealworldstudy
AT yangchangqing effectofentecavirontheintestinalmicroflorainpatientswithchronichepatitisbacontrolledcrosssectionalandlongitudinalrealworldstudy